This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mazzariol, A.
Right arrow Articles by Nikaido, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mazzariol, A.
Right arrow Articles by Nikaido, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2000, p. 1387-1390, Vol. 44, No. 5
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Contributions of the AmpC beta -Lactamase and the AcrAB Multidrug Efflux System in Intrinsic Resistance of Escherichia coli K-12 to beta -Lactams

Annarita Mazzariol,1,2 Giuseppe Cornaglia,1 and Hiroshi Nikaido2,*

Institute of Microbiology, University of Verona, Verona, Italy,1 and Department of Molecular and Cell Biology, University of California, Berkeley, California2

Received 7 October 1999/Returned for modification 19 January 2000/Accepted 1 February 2000


    ABSTRACT
Top
Abstract
Text
References

The roles of the AmpC chromosomal beta -lactamase and the AcrAB efflux system in levels of intrinsic resistance and susceptibility of Escherichia coli to beta -lactams were studied with a set of isogenic strains. MICs of ureidopenicillins, carbenicillin, oxacillin, and cloxacillin were drastically reduced by the inactivation of AcrAB, whereas those of the earlier cephalosporins were affected mostly by the loss of AmpC beta -lactamase.


    TEXT
Top
Abstract
Text
References

The beta -lactam antibiotics act by inhibiting penicillin-binding proteins. However, MICs seen with wild-type strains of gram-negative bacteria are usually significantly higher than the concentrations needed to bind and inhibit the penicillin-binding proteins because the access of beta -lactams to the targets is hindered by the presence of the outer membrane barrier and by their hydrolysis via the chromosomally coded AmpC-type beta -lactamase (20). This increase in MIC is called "intrinsic resistance" throughout this paper, although the absolute values of MIC for many compounds fall into the susceptible range for the purpose of clinical use.

AmpC belongs to class C (2) or group 1 (5) in the classification of beta -lactamases. Like most Enterobacteriaceae, Escherichia coli produces the AmpC enzyme (13), but in this case its production is at a low level and is not inducible because there is no ampR regulatory gene in this species (3). However, even this low level of the enzyme can contribute to the intrinsic resistance of E. coli, as shown earlier by the comparison of beta -lactam susceptibility in strains producing this enzyme at different levels (20), a study that concluded that the MICs could be explained quantitatively by the beta -lactamase-mediated hydrolysis and the limitation of influx through the outer membrane barrier.

More recently, however, multidrug efflux pumps, and especially the constitutively expressed AcrAB system (17) in E. coli, were shown to affect intrinsic beta -lactam resistance (14), and comparison of various beta -lactam compounds in Salmonella enterica serovar Typhimurium, which does not produce the AmpC beta -lactamase, showed that beta -lactams with lipophilic side chains are pumped out effectively by this system (18). Because these recent results do not fit completely with the conclusion arrived at more than 10 years ago (20), we investigated the role of the AmpC chromosomal beta -lactamase and the AcrAB efflux system in intrinsic resistance of E. coli to beta -lactams.

A set of isogenic K-12 strains lacking the AmpC enzyme and/or the AcrAB transport function was created for this purpose. We first amplified the ampC gene by PCR, using CGAGAATTCGGACCCGATGGAATTTTAC and GTCCGGATCCCATTACCCTGGCGCATCGT as primers. The amplified fragment was cloned between the BamHI and EcoRI sites in pUC19. We then inserted the spectinomycin marker (21) in the SmaI site within the ampC gene. The linearized plasmid was transformed into the recBC host strain JC 7623 [K-12 F- argE3 hisG4 leuB6 Delta (gpt-proA)62 thr-1 thi-1 ara-14 galK2 lacY1 mtl-1 xyl-1 kdgK51 tsx-33 recB21 recC22 sbcB15 supE44 rpsL31 rac] (6), and selection for spectinomycin resistance (100 µg/ml) resulted in the isolation of strain AM16, which contained the disrupted, chromosomal ampC::spc allele, whose presence was confirmed by PCR. All selection procedures for the ampC strains were done at 30°C because disruption of this gene has been reported to result in a marginally temperature-sensitive phenotype (4). The absence of detectable beta -lactamase activity in AM16 was confirmed by spectrophotometric assay of crude cell extracts with 0.1 mM cephaloridine and cephalothin as substrates. Although the presence of an AmpC homolog, AmpH, in E. coli has been described, AmpH totally lacks the ability to hydrolyze nitrocefin and most probably other beta -lactams as well (10). The strain JZM120 (14) was also a derivative of JC7623, containing a deletion that covers most of both acrA and acrB genes and a kanamycin marker inserted in exchange for the deleted sequence. The double mutant AM17 was obtained by P1 transduction of the Delta acrAB::kan allele from JZM120 into AM16. When a Western blot assay using anti-AcrA rabbit antibodies was done, AcrA could be detected only in JC7623 and AM16, not in JZM120 and AM17.

Using this set of strains, the drug susceptibility was tested by the broth microdilution method in Luria-Bertani medium at 30°C, with a standard inoculum of 104 cells (Table 1). All antibiotics used in this study were obtained from commercial sources.

                              
View this table:
[in this window]
[in a new window]
 
TABLE 1.   beta -Lactam MICs for a set of isogenic E. coli strainsa

With certain agents, inactivation of the ampC gene made E. coli more susceptible. This was observed most prominently with earlier cephalosporins such as cephalothin, cefamandole, and cephaloridine. A marginal (twofold) decrease in MIC was observed with ampicillin, mezlocillin, piperacillin, penicillin G, cefazolin, cefsulodin, cefoperazone, cefuroxime, and cefoxitin. These results can be compared with the rate of hydrolysis of these agents by the E. coli AmpC enzyme. However, because the rate varies with the concentration of the drug, a valid comparison requires the knowledge of the Km and Vmax for each substrate, as well as a somewhat arbitrary assumption of the drug concentration in the periplasm. We used the kinetic constants of the E. coli AmpC enzyme previously reported (8, 9, 20) and used as the periplasmic concentration the concentration at which the targets become inhibited (Cinh of reference 20), on the assumption that this concentration will be achieved when the external drug concentration is equal to MIC. In Table 2 we list, out of the compounds tested in Table 1, those for which hydrolysis rates could be calculated. A reasonably good correlation is seen between the hydrolysis rate in the cell and the effect of ampC disruption. (Although a fourfold decrease in MIC with cefamandole was somewhat larger than that expected from the hydrolysis rate, the MICs determined by twofold serial dilution have an inherent error of twofold. The kcat and Km values of the K-12 AmpC enzyme, kindly determined for cefamandole by A. Dubus and J.-M. Frère [personal communication], were 5.9 s-1 and 40 µM, respectively, close to those reported in reference 20.) Furthermore, with compounds that are hydrolyzed very slowly (with the expected rates of 0.003 pmol mg-1 s-1 or less), there was no effect of ampC disruption on MIC (Table 2), and similar results were obtained with the cephalosporins with quaternary ammonium-containing side chains at the 3 position, such as cefepime and cefpirome, which are hydrolyzed extremely slowly by the class C chromosomal enzymes (19) (Table 1). Penicillin G, which is expected to be hydrolyzed even faster than cephalothin, showed only a twofold decrease in MIC in a reproducible manner. We earlier observed a 16-fold decrease in MIC even in a mutant still producing about 10% of the wild-type activity of AmpC (20), and the MIC observed in the Delta acrAB ampC strain AM17 (Table 1) was far above the 50% inhibitory concentration earlier determined for E. coli penicillin-binding proteins (7). We believe that the most likely explanation is the overexpression of an efflux pump(s) other than AcrAB in the heavily mutagenized parent strain JC7623.

                              
View this table:
[in this window]
[in a new window]
 
TABLE 2.   Apparent contribution of AmpC beta -lactamase to MIC

Inactivation of the AcrAB efflux pump often produced a significant (more than twofold) decrease in MIC (Table 1). This was observed with oxacillin, cloxacillin, mezlocillin, piperacillin, azlocillin, carbenicillin, cefamandole, cefuroxime, and cefoxitin. Table 3 lists mostly those compounds that were tested in S. enterica serovar Typhimurium earlier (18). The extent of decrease in MIC due to the deletion of acrAB genes in E. coli was very similar to what has been observed in the S. enterica serovar Typhimurium acr mutant SH7616 and generally showed a correlation with the lipophilicity of the side chains (18). Although ureidopenicillins (azlocillin, mezlocillin, and piperacillin) were not included in the serovar Typhimurium study, these compounds contain lipophilic phenyl branches in their side chains, and for this reason their efflux by the AcrAB system was not unexpected. A large discrepancy was again found with penicillin G. Inactivation of AcrAB in E. coli produced only a twofold change in MIC, a surprisingly small change in contrast to the 32-fold decrease found in serovar Typhimurium (18); a possible explanation is presented above. In contrast to these compounds with lipophilic side chains, compounds with much less lipophilic side chains, such as cefmetazole and cefazolin, showed no evidence of significant efflux (Table 3), in agreement with our previous conclusion that efflux through AcrAB requires the presence of lipophilic substituents on the substrate molecules. Imipenem is also a poor substrate of AcrAB-type pumps (Table 3); this is consistent with the finding obtained with Pseudomonas aeruginosa. Thus, although the overproduction of the MexEF OprN system and increased resistance to imipenem occur simultaneously, the latter was shown to be the result of the decreased level of a basic amino acid channel OprD (11), through which imipenem permeation predominantly takes place.

                              
View this table:
[in this window]
[in a new window]
 
TABLE 3.   Apparent contribution of multidrug efflux to MIC

It is of interest to compare our results on acrAB inactivation with the recently reported data on the inactivation of the homologous mexAB oprM system in P. aeruginosa (15, 16). Both previous studies showed that the deletion of efflux genes results in a drastic decrease in the MIC of carbenicillin, cefoperazone, and piperacillin, in agreement with the present results. However, some of the P. aeruginosa data are surprising. Nakae et al. (16) report that their efflux mutant is strongly hypersusceptible to cefpirome, and Masuda et al. (15) report that after the removal of the beta -lactamase, further inactivation of the MexAB OprM system results in a 500-fold decrease in the MIC of cefmetazole, which contains a very hydrophilic side chain and does not appear to be a substrate of the AcrAB system. Possibly these differences are due to the differences in the substrate-binding sites of AcrB and MexB. An alternative explanation is that both P. aeruginosa studies (15, 16) used mutants in which oprM was inactivated. The OprM outer membrane channel was suggested to participate also in efflux systems other than MexAB (23) and was indeed shown recently to participate in the aminoglycoside efflux through MexXY (1). Thus, the P. aeruginosa studies are not strictly examining the effect of the AcrAB homolog MexAB.

In retrospect, the earlier MIC prediction scheme (20) included only those beta -lactams that are relatively hydrophilic (and thus cross the outer membrane rapidly) and are readily hydrolyzed by beta -lactamases, because these two conditions were prerequisites for obtaining reliable values of permeability coefficient across the outer membrane by the Zimmermann-Rosselet assay. Because lipophilic compounds were thus excluded (unintentionally) from the earlier study (20), most of the compounds tested were not good substrates for the AcrAB efflux system, and the calculated MICs were in reasonable agreement with the observed values without the inclusion of the efflux term. However, for compounds such as cloxacillin or oxacillin, hydrolysis is very slow but the efflux is quite efficient, and neglecting efflux would produce an extremely incorrect prediction. Thus, the MIC prediction scheme would certainly be improved if we could include efflux. Although an equation with an efflux term has been explicitly formulated (12), the difficulty at present is that kinetic constants of the efflux system are unknown, although some idea of the affinity of several substrates could be obtained based on the recent AcrB reconstitution study (22).

Which factor is more important in increasing MIC, efflux or beta -lactamase? The answer of course depends on the type of beta -lactam and the nature and activity of the beta -lactamase present. Thus, for E. coli, which produces only a low, constitutive level of class C beta -lactamase, efflux generally plays a significant role. Especially for these compounds that are hydrolyzed poorly by the AmpC enzyme and in addition contain lipophilic substituents (cloxacillin, oxacillin, carbenicillin, and ureidopenicillins), the effect of efflux is predominant. A similar situation is likely to exist for these compounds for wild-type strains of other Enterobacteriaceae and P. aeruginosa, which produce inducible class C enzymes that hydrolyze these compounds only very slowly (8, 9). In contrast, for those compounds that are rapidly hydrolyzed by chromosomal or plasmid-coded beta -lactamases, hydrolysis tends to be a more important mechanism, and in strains producing high levels of such enzymes, the contribution of efflux will be hardly visible.


    ACKNOWLEDGMENTS

This study was supported in part by a grant from the U.S. Public Health Service (AI-09644).


    FOOTNOTES

* Corresponding author. Mailing address: Department of Molecular and Cell Biology, Room 229, Stanley Hall, University of California, Berkeley, CA 94720-3206. Phone: (510) 642-2027. Fax: (510) 643-9290. E-mail: nhiroshi{at}uclink4.berkeley.edu.


    REFERENCES
Top
Abstract
Text
References

1. Aires, J. R., T. Köhler, H. Nikaido, and P. Plésiat. 1999. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob. Agents Chemother. 43:2624-2628[Abstract/Free Full Text].
2. Ambler, R. P. 1980. The structure of beta -lactamases. Philos. Trans. R. Soc. Lond. B 289:321-331[Abstract/Free Full Text].
3. Bennett, P. M., and I. Chopra. 1993. Molecular basis of beta -lactamase induction in bacteria. Antimicrob. Agents Chemother. 37:153-158[Free Full Text].
4. Bishop, R. E., and J. H. Weiner. 1993. Complementation of growth defect in an ampC deletion mutant of Escherichia coli. FEMS Microbiol. Lett. 114:349-354[CrossRef][Medline].
5. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for beta -lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233[Medline].
6. Cohen, A., and A. J. Clark. 1986. Synthesis of linear plasmid multimers in Escherichia coli K-12. J. Bacteriol. 167:327-335[Abstract/Free Full Text].
7. Curtis, N. A. C., D. Orr, G. W. Ross, and M. G. Boulton. 1979. Affinities of penicillins and cephalosporins for the penicillin-binding proteins of Escherichia coli K-12 and their antibacterial activity. Antimicrob. Agents Chemother. 16:533-539[Abstract/Free Full Text].
8. Galleni, M., and J.-M. Frère. 1988. A survey of the kinetic parameters of class C beta -lactamases: penicillins. Biochem. J. 255:119-122[Medline].
9. Galleni, M., G. Amicosante, and J.-M. Frère. 1988. A survey of the kinetic parameters of class C beta -lactamases: cephalosporins and other beta -lactam compounds. Biochem. J. 255:123-129[Medline].
10. Henderson, T. A., K. D. Young, S. A. Denome, and P. K. Elf. 1997. AmpC and AmpH, proteins related to the class C beta -lactamases, bind penicillin and contribute to the normal morphology of Escherichia coli. J. Bacteriol. 179:6112-6121[Abstract/Free Full Text].
11. Köhler, T., M. Michéa-Hamzehpour, U. Henze, N. Gotoh, L. K. Curty, and J. C. Pechère. 1997. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol. Microbiol. 23:345-354[CrossRef][Medline].
12. Lakaye, B., A. Dubus, S. Lepage, S. Groslambert, and J.-M. Frère. 1999. When drug inactivation renders the target irrelevant to antibiotic resistance: a case story with beta -lactams. Mol. Microbiol. 31:89-101[CrossRef][Medline].
13. Livermore, D. M. 1995. beta -Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8:557-584[Abstract].
14. Ma, D., D. N. Cook, M. Alberti, N. G. Pon, H. Nikaido, and J. E. Hearst. 1995. Genes acrA and acrB encode a stress-induced efflux system of Escherichia coli. Mol. Microbiol. 16:45-55[CrossRef][Medline].
15. Masuda, N., N. Gotoh, C. Ishii, E. Sakagawa, S. Ohya, and T. Nishino. 1999. Interplay between chromosomal beta -lactamase and the MexAB-OprM efflux system in intrinsic resistance to beta -lactams in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:400-402[Abstract/Free Full Text].
16. Nakae, T., A. Nakajima, T. Ono, K. Saito, and H. Yoneyama. 1999. Resistance to beta -lactam antibiotics in Pseudomonas aeruginosa due to interplay between the MexAB-OprM efflux pump and beta -lactamase. Antimicrob. Agents Chemother. 43:1301-1303[Abstract/Free Full Text].
17. Nikaido, H. 1996. Multidrug efflux pumps of gram-negative bacteria. J. Bacteriol. 178:5853-5859[Free Full Text].
18. Nikaido, H., M. Basina, V. Nguyen, and E. Y. Rosenberg. 1998. Multidrug efflux pump AcrAB of Salmonella typhimurium excretes only those beta -lactam antibiotics containing lipophilic side chains. J. Bacteriol. 180:4686-4692[Abstract/Free Full Text].
19. Nikaido, H., W. Liu, and E. Y. Rosenberg. 1990. Outer membrane permeability and beta -lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob. Agents Chemother. 34:337-342[Abstract/Free Full Text].
20. Nikaido, H., and S. Normark. 1987. Sensitivity of Escherichia coli to various beta -lactams is determined by the interplay of outer membrane permeability and degradation by periplasmic beta -lactamases: a quantitative predictive treatment. Mol. Microbiol. 1:29-36[CrossRef][Medline].
21. Prentki, P., A. Binda, and A. Epstein. 1991. Plasmid vectors for selecting IS-1 promoted deletions in cloned DNA: sequence analysis of the omega interposon. Gene 103:17-23[CrossRef][Medline].
22. Zgurskaya, H. I., and H. Nikaido. 1999. Bypassing the periplasm: reconstitution of the AcrAB multidrug efflux pump of Escherichia coli. Proc. Natl. Acad. Sci. USA 96:7190-7195[Abstract/Free Full Text].
23. Zhao, Q., X.-Z. Li, R. Srikumar, and K. Poole. 1998. Contribution of outer membrane efflux protein OprM to antibiotic resistance in Pseudomonas aeruginosa independent of MexAB. Antimicrob. Agents Chemother. 42:1682-1688[Abstract/Free Full Text].


Antimicrobial Agents and Chemotherapy, May 2000, p. 1387-1390, Vol. 44, No. 5
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Nagano, K., Nikaido, H. (2009). Kinetic behavior of the major multidrug efflux pump AcrB of Escherichia coli. Proc. Natl. Acad. Sci. USA 106: 5854-5858 [Abstract] [Full Text]  
  • Poole, K. (2005). Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56: 20-51 [Abstract] [Full Text]  
  • Kaczmarek, F. S., Gootz, T. D., Dib-Hajj, F., Shang, W., Hallowell, S., Cronan, M. (2004). Genetic and Molecular Characterization of {beta}-Lactamase-Negative Ampicillin-Resistant Haemophilus influenzae with Unusually High Resistance to Ampicillin. Antimicrob. Agents Chemother. 48: 1630-1639 [Abstract] [Full Text]  
  • Hirakawa, H., Nishino, K., Yamada, J., Hirata, T., Yamaguchi, A. (2003). {beta}-Lactam resistance modulated by the overexpression of response regulators of two-component signal transduction systems in Escherichia coli. J Antimicrob Chemother 52: 576-582 [Abstract] [Full Text]  
  • Nishino, K., Yamada, J., Hirakawa, H., Hirata, T., Yamaguchi, A. (2003). Roles of TolC-Dependent Multidrug Transporters of Escherichia coli in Resistance to {beta}-Lactams. Antimicrob. Agents Chemother. 47: 3030-3033 [Abstract] [Full Text]  
  • Tenover, F. C., Raney, P. M., Williams, P. P., Rasheed, J. K., Biddle, J. W., Oliver, A., Fridkin, S. K., Jevitt, L., McGowan, J. E. Jr. (2003). Evaluation of the NCCLS Extended-Spectrum {beta}-Lactamase Confirmation Methods for Escherichia coli with Isolates Collected during Project ICARE. J. Clin. Microbiol. 41: 3142-3146 [Abstract] [Full Text]  
  • Van Bambeke, F., Glupczynski, Y., Plesiat, P., Pechere, J. C., Tulkens, P. M. (2003). Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother 51: 1055-1065 [Full Text]  
  • Yigit, H., Anderson, G. J., Biddle, J. W., Steward, C. D., Rasheed, J. K., Valera, L. L., McGowan, J. E. Jr., Tenover, F. C. (2002). Carbapenem Resistance in a Clinical Isolate of Enterobacter aerogenes Is Associated with Decreased Expression of OmpF and OmpC Porin Analogs. Antimicrob. Agents Chemother. 46: 3817-3822 [Abstract] [Full Text]  
  • Oliver, A., Weigel, L. M., Rasheed, J. K., McGowan, J. E. Jr., Raney, P., Tenover, F. C. (2002). Mechanisms of Decreased Susceptibility to Cefpodoxime in Escherichia coli. Antimicrob. Agents Chemother. 46: 3829-3836 [Abstract] [Full Text]  
  • Lakaye, B., Dubus, A., Joris, B., Frere, J.-M. (2002). Method for Estimation of Low Outer Membrane Permeability to {beta}-Lactam Antibiotics. Antimicrob. Agents Chemother. 46: 2901-2907 [Abstract] [Full Text]  
  • Yu, J.-L., Grinius, L., Hooper, D. C. (2002). NorA Functions as a Multidrug Efflux Protein in both Cytoplasmic Membrane Vesicles and Reconstituted Proteoliposomes. J. Bacteriol. 184: 1370-1377 [Abstract] [Full Text]  
  • Raimondi, A., Sisto, F., Nikaido, H. (2001). Mutation in Serratia marcescens AmpC {beta}-Lactamase Producing High-Level Resistance to Ceftazidime and Cefpirome. Antimicrob. Agents Chemother. 45: 2331-2339 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mazzariol, A.
Right arrow Articles by Nikaido, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mazzariol, A.
Right arrow Articles by Nikaido, H.